Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ] [ Designated as safety issue: No ]The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
- Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: 1 year ] [ Designated as safety issue: No ]Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ] [ Designated as safety issue: No ]To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
|Study Start Date:||January 2011|
|Study Completion Date:||January 2012|
Postmenopausal Women on Endocrine Therapy
Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01300871
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 3M9|
|Principal Investigator:||Lindsay Carlsson||University Health Network-Princess Margaret Hospital|